Dr. Ankit Mangla, MD

Medicare patients and services

Medicare patients, 2024

167

Services billed

657

Patients’ average age

73

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 5 companies reported 10 payments worth $16,460 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Ohio →

Industry-funded research

Named as a principal investigator on 8 industry-funded studies in 2025, from 5 companies. The companies reported $1,432,656 in research payments for these studies, mostly to the institutions running them.

• A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
  Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT05608291
• A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
  Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06246916
• Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
  Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT05352672
• A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
  Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06190951
• MEKRAF-AST-101
  Springworks Therapeutics, Inc.
• An openlabel phase 1 study to investigate PF08046031 in adults with advanced melanoma and other solid tumors
  Pfizer Inc.
• Brightline-1: A Phase II/III, randomized, open-label, multi-center study of brigimadlin (BI 907828) compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma
  Boehringer Ingelheim Pharmaceuticals, Inc.
• A phase II open label prospective single arm study to assess ability of eltrombopag to induce sustained remission in subjects with ITP who are refractory or relapsed after first line steroids n n
  Novartis Pharmaceuticals Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Cleveland

• David J. Adelstein, M.D.
• Roba Alhasan, M.D.
• Azka Ali, MD
• Mir Y. Ali, MD
• Steven W. Andresen, DO
• Dana E. Angelini, MD
• Joseph Baar, MD
• David L. Bajor, MD